Regulatory T cell (T reg ) therapy has been exploited in autoimmune disease, solid organ transplantation and in efforts to prevent or treat graft-versushost disease (GVHD). However, our knowledge on the in-vivo persistence of transfused T reg is limited. Whether T reg transfusion leads to notable changes in the overall T reg repertoire or whether longevity of T reg in the periphery is restricted to certain clones is unknown. Here we use T cell receptor alpha chain sequencing (TCR-a-NGS) to monitor changes in the repertoire of T reg upon polyclonal expansion and after subsequent adoptive transfer. We applied TCR-a-NGS to samples from two patients with chronic GVHD who received comparable doses of stem cell donor derived expanded T reg . We found that in-vitro polyclonal expansion led to notable repertoire changes in vitro and that T reg cell therapy altered the peripheral T reg repertoire considerably towards that of the infused cell product, to different degrees, in each patient. Clonal changes in the peripheral blood were transient and correlated well with the clinical parameters. We suggest that T cell clonotype analyses using TCR sequencing should be considered as a means to monitor longevity and fate of adoptively transferred T cells.
Introduction
Regulatory T cells (T reg ) have entered the clinic. Cell therapy with freshly isolated or expanded T reg is applied in autoimmunity, transplantation and graft-versus-host disease (GVHD) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Little is known about the stability and persistence of infused T reg in vivo. Flow cytometry has been used to monitor T reg quantitatively in the periphery post-transfer. Based on the expression of CD4, CD127, forkhead box protein 3 (FoxP3), and especially the high expression of CD25 on previously expanded T reg , T reg enumerations post-transfer could be tracked for 2 weeks in the case of third-party umbilical cord blood origin administered for GVHD prevention [9] , and up to 3 months in the case of stem cell donor-derived T reg for chronic GVHD (cGVHD) treatment [10] . Kinetics of transferred T reg in the peripheral blood seem to vary greatly between individuals [1, 6, 10] . Recently, Bluestone et al. reported tracking of autologous expanded T reg in type 1 diabetes patients by means of stable isotype labelling of T reg by adding deuterium-labelled glucose during in-vitro expansion. Chromatography-mass cytometric analysis of isolated T reg at different time-points post-cell therapy revealed 25% of peak labelling at 3 months and the detection of transferred T reg in the periphery for 1 year [1] . However, whether longevity is independent of the specificity of T reg or restricted to certain clones is unknown. We aimed to explore the feasibility of T cell receptor (TCR) next-generation sequencing (NGS) as a tool to measure T reg clonality after expansion and in-vivo persistence after adoptive transfer, and as a means to track changes in the clonal repertoire of infused allogeneic T reg with time. We chose T cell receptor (TCR)-a chain sequencing in this feasibility study, as this has been recently developed locally [11] . This is, to our knowledge, the first report exploiting T reg TCR-a-NGS after adoptive transfer of T reg .
Methods

Patient characteristics and T reg therapy
TCR-a-NGS was performed in two patients who received adoptive T reg therapy. Both patients suffered from treatmentrefractory chronic GVHD as defined by National Institute of Health (NIH) criteria [12] after fully matched allogeneic haematopoietic stem cell (HSC) transplantation. The patients received T reg infusions 40Á5 months (patient 1) and 28 months (patient 2) after HSC transplantation (40 and 21 months after developing GVHD). Both patients showed full donor chimerism at the time of T reg infusion. Details on original disease, graft characteristics, GVHD manifestation and discontinued GVHD medication are listed in Table 1 . Patient 1 showed severe skin chronic GVHD (III8/progressive, maculopapular rash), affected oral cavity (III8/progressive, lichenoid buccal mucosal lesions/ulcerations) and eyes (II8/stable; keratoconjunctivitis sicca). Patient 2 reported severe chronic GVHD affecting the skin (III8/stable, ulcerations, sclerotic features) and the oral cavity (II8/stable). T reg therapy and follow-up for both patients has been reported previously [10] . Briefly, T reg were isolated from a leucapheresis product collected from the original haematopoietic stem cell donor by CD8 1 depletion and CD25 11 enrichment, expanded for 12 days with two rounds of aCD3aCD28 bead stimulation (Dynabeads Human T-Activator; Invitrogen, Carlsbad, CA, USA) and high-dose interleukin (IL)-2 (Proleukin S; Novartis Pharma, Basel, Switzerland) in the presence of rapamycin. Viability of the final cell product was 98% (patient 1) and 94% (patient 2), as determined by trypan blue staining. Cells were infused at a dosage of 3Á7 3 10 6 T reg cells/kg (patient 1) or 3Á8 3 10 6 T reg cells/kg (patient 2). Adoptive transfer of T reg was conducted within a compassionate use programme. Immunomonitoring after T reg therapy was performed after informed consent within a study protocol approved by the local ethics review committee (protocol no. EK 206082008).
Sample processing
Samples for TCR-a-NGS included unexpanded donor T reg (CD4
1
CD25
high CD127 low T lymphocytes) and expanded donor T reg , and recipient T reg , CD8 1 T lymphocytes and
immediately prior to infusion and at several time-points after infusion (Table 3) . Cells used for TCR-a-NGS were enriched magnetically and subsequently fluorescence activated cell sorter (FACS) purified after staining with CD4-peridinin chlorophyll (PerCP), clone SK3; CD25-phycoerythrin (PE), clone M-A251; CD45RO-allophycocyanin (APC), clone UCHL1 (all from BD Biosciences, San Jose, CA, USA) and CD127-eFluor450, clone eBioDDR5 (eBioscience, San Diego, CA, USA). The procedure is outlined schematically in Fig. 3b . Cells were lysed in RLT buffer (RNeasy MiniKit; Qiagen, Hilden, Germany) with 1% b-mercaptoethanol, snap-frozen and stored at 2808C.
Library preparation and NGS sequencing for TCR-a chain
RNA was isolated from the frozen cell pellets using the RNeasy MiniKit (Qiagen). First-strand cDNA was synthesized utilizing the template switching protocol for TCR-a, and TCR-a amplified as described [11] . The final product was purified with the QIAquick polymerase chain reaction (PCR) purification kit (Qiagen). Barcoded libraries were pooled and 150 base pairs (bp) reads were generated using the Illumina HiSeq 2500 system. TCR CDR3 region sequences extraction and PCR error correction was carried out as described with MiTCR software (MiLaboratory, Moscow, Russia) [13, 14] . Non-productive TCR sequences were filtered out, resulting in an average of 70% usable reads from the total reads obtained.
Statistical analysis
Analyses were conducted using R (2.15.0 2012-03-30; The R Foundation for Statistical Computing, Vienna, Austria) and Konstanz information miner (KNIME) [15] . Simpson's Diversity Index was determined as described [16] , where an index of 0 is minimal and 1 is maximal diversity. In order to overcome the problem of differing sizes of different biological samples when comparing their Simpson's Diversity, we subsampled the same number of reads from each biological sample according to the smallest sample. This subsampling of reads was repeated 11 times, and the resulting Simpson Diversity indices were averaged. Pearson's correlation was calculated on proportions of clonotypes across time-points.
Results
Comparison of donor T reg repertoire with preinfusion recipient T reg repertoires
TCR-a reads within T reg were compared in the SC) recipient and the HSC donor at the time of T reg infusion, 40 months after bone marrow transplant (patient 1) and 28 months after peripheral blood HSC transplant (patient 2) ( Fig. 1 ). There was no overlap in the 100 most frequent TCR-a clonotypes seen between the recipient and donor T reg in patient 1. In contrast, in patient 2, 12 of the 100 most abundant clonotypes were shared between the recipient and donor. There was no obvious bias of these clonotypes with respect to their TCR-a variable (TRAV) and TCR-a joining (TRAJ) genes (data not shown).
TCR-a diversity is decreased after T reg expansion
We were able to examine the diversity of the TCR-a repertoire in the pre-expansion and expanded T reg in patient 2. Few cells were recovered for patient 1. In-vitro T reg expansion of the T reg for patient 2 was 18-fold, with a final purity of 91Á8% CD4 1 CD25 high CD127 low FoxP3 1 cells. We observed a similar gene usage pre-and post-expansion (Fig.  2a) . Despite this, there were clear changes in the repertoire as assessed by comparing the frequency of clonotypes preand post-expansion (Fig. 2b, left panel) . A large number of high-frequency clones from the isolated cell product were not detected in the expanded T reg sample, whereas others that had frequencies of < 0Á001% in the isolated T reg increased 100-1000-fold in their relative frequency in the expanded preparation. Of 987 clonotypes with read frequencies above 0Á01% in the isolated cell product, 416 (42%) were not detectable (read frequencies < 0Á0001%) in the expanded cell product. The 100 highest TCR-a clone frequencies were higher in the expanded T reg preparations than in the isolated T reg (P < 0Á0001) (Fig. 2b, right panel) . Simpson's diversity indices of the isolated and expanded clonotypes after mathematical subsampling were 0Á9996 in the pre-expanded T reg and 0Á9987 in the expanded T reg .
T reg TCR repertoire changes after T reg infusion
We asked whether transferred T reg can be detected in the periphery after infusion and whether the transfer leads to changes in the clonal distribution within the patient's T reg cell pool. For patient 1, a 4.6-fold increase in the proportion of T reg among the CD4 1 T cell pool was observed by flow cytometry 24 h post-infusion followed by a gradual decline from week 3 post-infusion (Fig. 3a, left graph) . TCR-a-NGS sequencing of T reg samples from this patient indicated a rapid change in the peripheral T reg repertoire upon T reg transfer, as shown by the lack of correlation comparing the repertoire pre-and 24 h post-transfusion (Fig. 4a , upper left plot and Fig. 4b , grey bars). Moreover, there was a marked correlation between the repertoire of the expanded T reg cell product and the patient's T reg repertoire at 24 h posttransfer, suggesting that the increase in T reg was a direct result of the infusion (Fig. 4a , lower left plot and Fig. 4b , black bars). The change in repertoires is also seen in the frequencies of the dominant TCR-a from the expanded T reg , the preinfusion and the 6Á5 weeks post-infusion repertoires (Fig. 4c, upper row ). An increased correlation between the patient's T reg repertoire and the expanded T reg pool compared to patient's repertoire pre-T reg transfer was observed for the first 3 weeks after infusion in this patient (Fig. 4a,b) . At and after 6Á5 weeks post-transfer the repertoire correlation between the expanded cell pool and the patients' cell pool in the periphery decreased markedly. Most of the highest-frequency TCR-a in the sample 6Á5 weeks postinfusion was represented in the preinfusion repertoire; few were found only in the expanded repertoire and some were found in both (Fig. 4c, upper panel) . We did not detect a change in the CD8 1 T cell repertoire upon T reg transfer within the monitored time-frame (Fig. 4b , lower left bar graph), and only minor changes in the repertoire of peripheral CD4
1 T effector memory cells (Fig. 4b , lower right graph). Interestingly, we observed a decrease in activation marker CD69-positive CD4 1 and CD8 1 T effector cells during the first 3 weeks post-T reg transfer by flow cytometry in this patient [10] . This was followed by a transient clinical response affecting skin and oral mucosa (grades III-II) from weeks 13 to 18 post-therapy and a reduction of the corticosteroid dose (Table 2) .
Despite infusion of a similar T reg dose and a similar high viability of the cell product, the T reg proportion among CD4 1 T cells in the peripheral blood of patient 2 did not increase after infusion as measured by flow cytometry (Fig. 3a, right  graph) . The T reg TCR-a repertoires 1 and 5 weeks postinfusion showed little correlation with the preinfusion or the expanded T reg repertoires (Fig. 4b, right panel) . Patient 2 showed no clinical response but stable disease from week 11 to 14 post-T reg therapy and GVHD progressed after week 5 (skin) ( Table 2) . Nevertheless, all the most frequent T reg TCR-a found 5 weeks post-infusion were seen in the preinfusion or the expanded T reg repertoires (Fig. 4c, bottom panels) .
Discussion
Using NGS-TCR-a sequencing, we have demonstrated changes in T reg repertoire following T reg cell therapy. The changes were associated with clinical outcome, suggesting that monitoring TCR repertoires following adoptive T cell therapy may be considered as a measure of cell engraftment.
The study was exploratory to assess whether T reg repertoires change after adoptive T reg cell therapy. Despite being (a) (b) Fig. 4 . Continued small, and thus largely descriptive, it provides insight into the information that can be gained by extensive TCR repertoire analysis of specific cell types, and shows clearly that it can be a useful tool in adoptive T cell therapy. The following observations were of interest. First, follow-up in two patients demonstrated markedly different outcomes with respect to T reg TCR repertoire changes. One patient (patient 2) had acquired a T reg TCR repertoire 28 months after HSC transplant that overlapped substantially with that of the HSC donor with respect to frequent TCR-a clonotypes, and showed only minor changes in the peripheral blood T reg TCR repertoire after T reg cell therapy despite a high viability of the cell product at the time of infusion. In contrast, the T reg TCR repertoire in the other patient (patient 1) was very different to that of the bone marrow donor, but changed dramatically to one resembling the (c) repertoire of the infused T reg cells after adoptive T reg cell therapy with a gradual return to a pre-adoptive T reg cell therapy profile during a period of 1-2 months. The diverse outcomes in the two patients hold promise that monitoring TCR repertoires following adoptive T cell therapy may provide clinically meaningful information. Of note, the CD8 1 TCR repertoires did not alter after adoptive T reg cell therapy, showing the specificity of the T reg changes in the patients. The small initial change in the CD4 1 T effector repertoire is biased most probably by the small sample size of the pretransfer sample (Table 3) . Donor characteristics differed between the two patients. Patient 1 received grafts from a 39-year-old unrelated matched donor and patient 2 from her 51-year-old sibling. Donor human leucocyte antigen (HLA) match and age have been shown to be associated with the risk of GVHD after allogeneic transplantation. We were also able to assess the T reg repertoire after in-vitro expansion on one preparation. Several investigators aim currently at prolonged expansion cultures using modified expansion protocols of up to 35 days and to three rounds of restimulation driven by restricted starting material and/or to obtain higher T reg doses [4, 9, 17] . A number of studies suggested polyclonality of the expanded cell pool using TCR Vb repertoire analysis by flow cytometry [9, 18] . Bluestone et al. reported recently the gene usage of bead-expanded T reg by TCR-b sequencing before and after a 14-day expansion protocol. Looking at gene usage only, the cell product appeared polyclonal despite an average 500-fold expansion [1] . We had an 18-fold expansion and were able to confirm polyclonality and a stable gene usage by TCR sequencing. However, we revealed marked changes in the clonal repertoire accompanied by a considerable decrease in diversity after expansion. This contrasts the negligible observed repertoire changes in some reports [19, 20] . This finding argues for further investigations by us and other sites aiming at and already reaching far higher numbers of in-vitro cell doublings before transfusion.
There are at least two limitations of all currently applied approaches to track T reg after adoptive transfer. First, T reg may undergo phenotypical changes including CD25 downregulation in vivo, as shown by Singh et al., and thus might not have been isolated by FACS prior to further analysis [21] . However, the findings of Bluestone et al., demonstrating that CD4
1 T cells other that T reg did not show signs of deuterium labelling after sorting, suggest the plausibility of our approach [1] . As infused T reg are CD45RO 1 , the additional use of this marker for sorting post-infusion may improve the ability to track cells by TCR sequencing. The use of paired TCR-a and TCR-b sequencing using recent techniques [22] is also likely to improve tracking. Secondly, we are currently constrained to limit our analyses to peripheral blood. T reg probably migrate to lymphoid tissue or sites of inflammation where they cannot be detected, and might thus be invisible to us, rather than cleared [23] . Their presence in the affected tissue might, at the same time, be of higher relevance for clinical benefit. Based on the similar product viability and dosage, we hypothesize that a retention in lymph nodes or a more rapid sequestration into peripheral tissue might explain the lack of evidence of infused T reg in the peripheral blood of patient 2.
In conclusion, we found that TCR-a-NGS T reg is a versatile method to track changes in the T reg repertoire with time. Our results indicate that patients can partially adopt donor T reg specificities after HSC transplantation, and that adoptive T reg cell therapy can lead to transient clonal changes within the circulating peripheral T reg repertoire. The degree of these repertoire changes can differ substantially between individuals. Some of the transferred T reg clones appeared to reside longer in the periphery than others, and overall clonal changes are of transient nature. Thus, we advocate the use of TCR repertoire analyses, together with analyses such as the use of deuterium labelling of cells in patients undergoing adoptive T cell therapies. piled clinical data, U. O. supervised immunomonitoring for patient 2, A. D. performed sequencing, M. B. initiated and supervised T reg cell therapy and critically read the manuscript, E. B. initiated, planned and supervised the study and contributed to manuscript writing; A. E. planned and supervised the study, performed T cell receptor library preparation, data analysis and contributed to manuscript writing. 
